Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors

Summary

We report our experience of cryoablation as a local and analgesic treatment for inoperable or recurring desmoid tumors. This study includes 34 patients who underwent percutaneous cryoablation of 41 desmoid tumors between July 2012 and September 2016. All patients underwent pain assessment using a visual analog scale (VAS) and preoperative imaging. All cryoablation procedures were performed using the same cryoablation system. Patients received clinical and radiological follow-up at 6 months post-procedure, with pain-rating and adverse events being recorded. A long-term follow-up was achieved until 31 December 2018. Radiological tumor response was determined by tumor measurements using RECIST 1.1. Twelve patients benefitted from curative treatment on 100% of the tumor volume, but 22 patients received debulking treatment because of the risk of neighboring structures. Two patients had a postoperative hematoma grade 2 of the CIRSE classification system for complications, and two patients had grade 4 complications involving palsy of the common fibular nerve. Disease-free survival at 3 years was 42.2%. The mean VAS pain scores were 5.7 and 2.4 at pretreatment and 6 months, respectively, showing a mean reduction of 3.3 (p?<?0.001). At 6 months, all measured tumor dimensions were significantly lower than pretreatment. Cryoablation is an effective therapeutic option for the local treatment and for the analgesic management of desmoid tumors.